Integrated DNA Technologies (IDT) stands at the forefront of genomics innovation, driving advancements that are shaping the future of personalized medicine. In this blog, we spotlight the many pivotal contributions—from enabling the world’s first personalized CRISPR therapy to launching transformative tools and strategic collaborations that exemplify how IDT is accelerating the pace of genomic discovery. The following sections showcase real-world examples of leadership and impact throughout key emerging areas within genomics in 2025.

1. Personalized CRISPR therapies move beyond the clinic

Earlier this year, Danaher Corporation sister companies, Aldevron and IDT reshaped the future of precision medicine by supporting the successful manufacture of the world’s first personalized CRISPR gene editing drug to treat an infant with urea cycle disorder (UCD).

We contributed to the technically complex N of 1 therapy by supplying a new guide RNA (gRNA) sequence and custom off-target analysis services—working under condensed timelines and operating with urgency and precision. The process, from ideation to FDA approval to administration, took just six months—three times faster than the average speed of these therapies. The monumental outcome was featured in a study published in The New England Journal of Medicine and provided a proof of concept for the potential of safe, and effective, personalized CRISPR therapy in the future.

2. AI & expert protein design merge to transform genomic data analysis and interpretation

In October, IDT and Profluent Bio, a leader in artificial intelligence (AI)-first protein design, launched a strategic collaboration to leverage AI to design and optimize next-generation enzymes. The partnership brought together Profluent’s generative AI platform with our expertise in enzymology and genomics to offer a range of benefits—from streamlined use of in silico designs to ready-to-use biological tools. By leveraging our infrastructure and global manufacturing to test, validate, and scale Profluent-designed sequences, we enable researchers to fast track new paths for developing novel enzyme variants that will lead to transformative growth in epigenetics and cancer research.

3. First-to-market solutions to drive infectious disease research

The launch of our first-to-market, complete solution PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels marked a significant advancement for the infectious disease community, providing researchers with powerful, optimized tools to rapidly identify and characterize a broad spectrum of pathogens. By enabling high-throughput, multiplexed analysis, and seamless integration into existing workflows, these solutions will accelerate disease surveillance, support timely public health responses, and drive innovation in drug discovery.

4. Next-generation sequencing and real-time genomics in expanded settings

To address a critical need of cancer researchers, we launched the xGen™ Hybridization and Wash v3 Kit. This enhanced solution delivers tangible benefits by improving next generation sequencing (NGS) workflows and enabling more reliable variant detection—even from challenging, low-input samples. Its automation-friendly design reduces hands-on time by 20%, eliminates the need for heated buffers, and allows users to move from sample to sequencer in a single workday—directly increasing lab efficiency and throughput. With compatibility for a wide range of sample types, this solution empowers scientists to confidently advance minimal residual disease (MRD) research and rapidly adapt to evolving cancer research needs.

Additionally, the strategic partnership between IDT and Beckman Coulter Life Sciences to automate Archer™ FUSIONPlex™ and VARIANTPlex™ targeted sequencing assays and xGen™ Hybrid Capture workflows on the new Biomek i3 Benchtop Liquid Handler marked a major advancement for oncology research. This collaboration enables laboratories to automate and streamline complex sequencing workflows with greater precision and scalability. By integrating targeted sequencing assays and hybrid capture workflows on an advanced liquid handling platform, researchers save critical time while enhancing precision, scalability, and reproducibility to identify variants and drive precision medicine discoveries.

5. CRISPR infrastructure and regulatory support services expansion

Demonstrating our commitment to advancing CRISPR-based therapies, we recently expanded our translational research portfolio with two new innovative solutions:

  • Chemically synthesized gRNAs in a variety of modification and purity options, including high-purity HPLC-purified gRNAs that are quickly available in multiple yields.
  • Alt-R™ HDR Enhancer Protein, a newly developed solution designed to facilitate an up to two-fold increase in HDR efficiency in challenging cells, including iPSCs and HSPCs.

And, to support teams transitioning from the lab to the clinic, we introduced key IND-enablement services:

  • Regulatory Affairs support services to offer confidence in precision, reliability, and compliance at every step.
  • UNCOVERseq, our off-target nomination service, which utilizes enhanced GUIDE-seq™ methodology, and when combined with their rhAmpSeq™ CRISPR Analysis System, support the identification and confirmation off-target sites to support the safety and efficiency of therapeutic development.

Combined, these offerings empower scientists to accelerate discovery, improve editing efficiency, and enhance on-target genome editing.

As we plan for the year ahead, our teams remain committed to the IDT legacy of pioneering innovative technologies and embarking on strategic collaborations that position us as a trusted partner within the genomics community.